^
Association details:
| Biomarker: | HR positive + ER overexpression |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
246P - Correlation of MIB1 Labeling Index and Hormone Receptor Status with Survival in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors and Letrozole
Published date:
05/07/2023
Excerpt:
A total of 97 metastatic HR+/Her2- breast cancer female patients were selected from our database who received CDK 4/6 inhibitors plus letrozole first-line treatment....Real-world data of patients receiving palbociclib or ribociclib in combination with letrozole show that these CDK4/6 inhibitors are more effective in patients with higher ER expression.
Secondary therapy:
letrozole
